Shuttle Pharmaceuticals Holdings Inc SHPH

Morningstar Rating
$5.51 +0.80 (16.99%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SHPH is trading at a LOCK|S<!@C premium.
Price
$4.71
Fair Value
LOCK|JP!<st
Uncertainty
LOCK|Qx jx!z
1-Star Price
LOCK|.Ds&FTt
5-Star Price
LOCK|v<$<Y?G
Economic Moat
LOCK|@$x
Capital Allocation
—

Trading Information

Previous Close Price
$4.71
Day Range
$4.81–5.75
52-Week Range
$2.58–55.90
Bid/Ask
$5.51 / $5.65
Shares Outstanding
4.76M
Market Cap
$26.25M
Volume/Avg
208,500 / 1M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
2

Valuation

Metric
SHPH
Price/Earnings (Normalized)
—
Price/Book Value
0.25
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
SHPH
Quick Ratio
0.03
Current Ratio
0.11
Interest Coverage
−207.24
Quick Ratio
SHPH

Profitability

Metric
SHPH
Return on Assets (Normalized)
−100.59%
Return on Equity (Normalized)
−182.87%
Return on Invested Capital (Normalized)
−170.50%
Return on Assets
SHPH

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|&X@V?dMLOCK|&G>!P$68B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|^%gLXf^#LOCK|z!T#N$46B
Haleon PLC ADR
HLN
LOCK|v?Sx<kLOCK|RHj$40B
Zoetis Inc Class A
ZTS
LOCK|%q^pvp<LOCK|Qt$30B
Viatris Inc
VTRS
LOCK|lkJLGSLOCK|>N$20B
Elanco Animal Health Inc
ELAN
LOCK|$<$LOCK|K>$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|FQ$%SbLOCK|j%$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|Q<bQt<!LOCK|^@$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|vM@xShsLOCK|QHVN@$2B
Perrigo Co PLC
PRGO
LOCK|$vHp%HLOCK|Gyy$2B

Sponsor Center